<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307930</url>
  </required_header>
  <id_info>
    <org_study_id>A10-3616</org_study_id>
    <secondary_id>5UL1RR024982-02</secondary_id>
    <nct_id>NCT01307930</nct_id>
  </id_info>
  <brief_title>Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations</brief_title>
  <official_title>Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will find how weight affects the dosing of a drug called anidulafungin. Currently,
      the amount of anidulafungin a patient receives is the same regardless of the patient's
      weight. BMI groups were for enrollment purposes only and not used for ordinal data analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to measure drug concentrations in the blood of volunteers administered
      a single intravenous dose of anidulafungin. The volunteers to be enrolled will not have
      either candidiasis or any other fungal infection. This is a single center study. Up to a
      total of 35 adult volunteers will be consented for the study at the Clinical and
      Translational Research Center (CTRC). Eighteen of these volunteers are needed to complete the
      study. The others will likely be screen failures, which is more likely in the BMI &gt; 40 kg/m2
      group. Volunteers will be admitted to the CTRC for an overnight stay. Half will be female and
      half male. Six volunteers will have a body mass index (BMI) less than 25 kg/m2, six will have
      a BMI 25-40 kg/m2, and six will have a BMI greater than 40 kg/m2.

      ** BMI groups will only be used for patient enrollment and not for data analysis. total body
      weight will be used as a continuous variable for data analysis. **

      Volunteers will have height and weight measured after they have consented to participate. All
      volunteers in each category will receive a single dose of intravenous anidulafungin of 100
      mg. The volunteers will have blood drawn via an intravenous catheter just prior to the dose,
      and then at 1.5, 8, 16, and 24h after the drug dose. The intravenous catheter is then removed
      after the 24h blood draw, and the volunteer discharged from the study. The volunteer will be
      asked to return to the CTRC outpatient center at 48 and 72 hours to have the final 2 blood
      draws conducted. Subjects who are excluded from study participation due to their laboratory
      results will be provided with a copy of their results and an explanation of the reason for
      ineligibility.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Clearance of Anidulafungin</measure>
    <time_frame>0-72 hours</time_frame>
    <description>How quickly the body eliminates anidulafungin after a single dose</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obesity</condition>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>Anidulafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anidulafungin</intervention_name>
    <description>Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)</description>
    <arm_group_label>Anidulafungin</arm_group_label>
    <other_name>Eraxis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, age &gt; 18 years old, of all racial and ethnic origins.

          -  Non-English-speaking Spanish speakers will be included in the study.

          -  The investigators are recruiting six normal or underweight (BMI &lt; 25 kg/m2), six
             overweight or obese (BMI 25-40 kg/m2), and six extremely obese (BMI &gt; 40 kg/m2) for
             this study. This index is calculated using the volunteer's height and weight (Formula:
             weight (lb) / [height (in)]2 x 703). Half of each group will be male; the other half
             will be female.

        Exclusion Criteria:

          -  Pregnant or nursing or unwilling to use a reliable contraception method during the
             study. The effects of anidulafungin on pregnancy are unknown. In addition, the
             metabolic changes that accompany pregnancy may alter the concentration-time profile of
             anidulafungin, so that the pregnancy and postpartum state would be a confounding
             variable.

          -  Abnormal liver function tests: transaminases &gt; 3 times upper limit of normal, Alkaline
             phosphatase &gt; 3 times upper limit of normal, total bilirubin &gt; 3 times upper limit of
             normal.

          -  History of allergies to echinocandins.

          -  Echinocandins are contraindicated for any reason.

          -  Volunteers unwilling to comply with study procedures.

          -  Suspected or documented systemic fungal infection.

          -  Concomitant use of rifamycins, tacrolimus, or cyclosporine.

          -  Current participation or previous participation within 28 days of enrollment in
             another research study that involves the use of medication, contrast, or any other
             compound that may alter blood count and/or blood chemistry (liver function, kidney
             function or electrolyte balance) (Unless waved by PI).

          -  Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study
             enrollment (Unless waved by PI).

          -  Creatinine Clearance &lt; 70 ml/min as estimated by the Cockcroft-Gault equation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Hall, PharmD, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech UHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <results_first_submitted>July 23, 2018</results_first_submitted>
  <results_first_submitted_qc>January 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2019</results_first_posted>
  <disposition_first_submitted>February 4, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 22, 2014</disposition_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University Health Sciences Center</investigator_affiliation>
    <investigator_full_name>Ron Hall</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Echinocandin</keyword>
  <keyword>Obesity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Fungal infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anidulafungin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anidulafungin</title>
          <description>The study will have 18 participants complete the 72 hour sampling period. Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
Anidulafungin: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anidulafungin</title>
          <description>Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
Anidulafungin: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Clearance of Anidulafungin</title>
        <description>How quickly the body eliminates anidulafungin after a single dose</description>
        <time_frame>0-72 hours</time_frame>
        <population>Noncompartmental analysis of anidulafungin clearance</population>
        <group_list>
          <group group_id="O1">
            <title>Anidulafungin</title>
            <description>Single dose of 100 mg by IV infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Clearance of Anidulafungin</title>
          <description>How quickly the body eliminates anidulafungin after a single dose</description>
          <population>Noncompartmental analysis of anidulafungin clearance</population>
          <units>L/hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.72" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 days</time_frame>
      <desc>Adverse events were collected upon report of the participant to study staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anidulafungin</title>
          <description>Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
Anidulafungin: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Event 1: Numbness near lips, SOB, itchiness, diffuse rash near arms and chest, wheezing (not life threatening, resolved with benadryl)
Event 2: Infusion, facial numbness with bright red flushing rash</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Hall</name_or_title>
      <organization>TTUHSC</organization>
      <phone>2143589009</phone>
      <email>ronald.hall@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

